1. Home
  2. FNKO vs SGMT Comparison

FNKO vs SGMT Comparison

Compare FNKO & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Funko Inc.

FNKO

Funko Inc.

HOLD

Current Price

$4.06

Market Cap

192.7M

ML Signal

HOLD

Logo Sagimet Biosciences Inc. Series A

SGMT

Sagimet Biosciences Inc. Series A

HOLD

Current Price

$5.45

Market Cap

204.2M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
FNKO
SGMT
Founded
2017
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Recreational Games/Products/Toys
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
192.7M
204.2M
IPO Year
2017
2023

Fundamental Metrics

Financial Performance
Metric
FNKO
SGMT
Price
$4.06
$5.45
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
9
Target Price
$5.50
$27.00
AVG Volume (30 Days)
1.1M
845.8K
Earning Date
03-05-2026
03-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$928,842,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$10.54
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.22
$1.73
52 Week High
$14.28
$11.41

Technical Indicators

Market Signals
Indicator
FNKO
SGMT
Relative Strength Index (RSI) 56.64 40.85
Support Level $3.89 $5.02
Resistance Level $4.31 $7.20
Average True Range (ATR) 0.30 0.49
MACD -0.01 -0.01
Stochastic Oscillator 58.08 19.91

Price Performance

Historical Comparison
FNKO
SGMT

About FNKO Funko Inc.

Funko Inc is an USA based pop culture consumer products company. It creates whimsical, fun, and different products that enable the customer to express their affinity for their favorite through the movie, TV show, video game, musician, or sports team. The company's current products are principally figures, fashion accessories, apparel, plush products, accessories, homewares, and NFTs. The company sells its products through a diverse network of retail customers across multiple retail channels, including specialty retailers, mass-market retailers, and e-commerce sites. The company generates the majority of its revenue from the core collectibles products.

About SGMT Sagimet Biosciences Inc. Series A

Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.

Share on Social Networks: